Sobuzoxane

• CAT Number: I036461
• CAS Number: 98631-95-9
• Molecular Formula: C22H34N4O10
• Molecular Weight: 514.53
• Purity: 98%
• Synonyms: Sobuzoxane
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate
• InChI: InChI=1S/C22H34N4O10/c1-15(2)11-33-21(31)35-13-25-17(27)7-23(8-18(25)28)5-6-24-9-19(29)26(20(30)10-24)14-36-22(32)34-12-16(3)4/h15-16H,5-14H2,1-4H3
• InChIKey: OCOKWVBYZHBHLU-UHFFFAOYSA-N
• SMILES: O=C(CN(CCN(C1)CC(N(COC(OCC(C)C)=O)C1=O)=O)C2)N(COC(OCC(C)C)=O)C2=O

Sobuzoxane(CAT: I036461) is a cardioprotective agent and derivative of dexrazoxane, primarily utilized in oncology and cardiology research. It is known for its ability to mitigate the cardiotoxic effects of anthracycline-based chemotherapy, such as doxorubicin, by chelating iron and preventing free radical formation. Sobuzoxane is also investigated for its role in DNA topoisomerase II inhibition, contributing to its protective and potential anticancer effects. Researchers use Sobuzoxane to explore mechanisms of cardioprotection, chemotherapy-associated toxicity, and novel strategies to improve cancer treatment outcomes while preserving cardiac function. Its dual action makes it a critical tool for advancing translational research in cancer therapeutics and cardiotoxicity prevention.